(NASDAQ: BCRX) Biocryst Pharmaceuticals's forecast annual revenue growth rate of -3.98% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.24%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.13%.
Biocryst Pharmaceuticals's revenue in 2026 is $961,510,000.On average, 12 Wall Street analysts forecast BCRX's revenue for 2026 to be $186,372,152,507, with the lowest BCRX revenue forecast at $176,478,995,614, and the highest BCRX revenue forecast at $193,545,656,127. On average, 12 Wall Street analysts forecast BCRX's revenue for 2027 to be $193,283,210,873, with the lowest BCRX revenue forecast at $170,429,889,800, and the highest BCRX revenue forecast at $216,113,375,011.
In 2028, BCRX is forecast to generate $219,049,159,670 in revenue, with the lowest revenue forecast at $168,538,740,173 and the highest revenue forecast at $258,328,466,076.